Japanese tech giant Olympus is shuttering its U.S. biotech business and looking to sell off the New Hampshire plant that makes the OP-1 bone growth putty it bought from Stryker in 2010, spelling layoffs for some 200 workers.
Olympus (PINK:OCPNY) said it's shutting down its U.S. biotech business after failing to "gain the traction necessary to build a broader regenerative medicine portfolio," meaning layoffs for the unit's 200 workers.
A $2.6 million deal to settle a shareholder's lawsuit filed over the $1.7 billion accounting scandal that slashed 50% from Olympus Corp. in 2011.
A shareholder's lawsuit filed against Olympus (PINK:OCPNY) over a $1.7 billion accounting scandal is slated for a $2.6 million settlement after a federal judge granted preliminary approval to the deal last week.
Group purchasing organization Premier inked a deal with Olympus America for the company's Thunderbeat surgical tool, signing it up under the GPO’s program for innovative new technologies.
Olympus America, a Center Valley, Pa.-based commercial camera and medical supply maker, landed a contract to supply surgical tools to members of group purchasing organization Premier healthcare alliance.
The FDA clears Olympus for its high definition 3D video imaging system for laparoscopic surgery.
Olympus (PINK:OCPNY) won 510(k) clearance for its Articulating HD 3D laparoscopic surgical video system, which provides an additional 3D option to the company's Evis Exera III imaging system.
Sony Corp. plans to acquire an 11% stake in beleaguered Olympus Corp. for $642 million.
Sony Corp. (TYO:6758) plans to become the largest shareholder in Olympus (TYO:7733) with a $642 million investment that will give it an 11% stake in Olympus.
Japan's Terumo Corp. proposes a merger with Olympus Corp., aiming for a buyout to block rival companies' advances.
Asian medical device giant Terumo Corp. (TYO:4543) confirmed rumors of a proposed buyout of Olympus (PINK:OCPNY) in the aftermath of a $1.7 billion accounting scandal.
Stryker's plans to cut more than 100 jobs by closing 2 New York manufacturing facilities will begin in September and continue on a rolling basis until the end of the year, just ahead of implementation of the 2.3% medical device tax.
Stryker (NYSE:SYK) is making good on plans to cut more than 100 positions by closing 2 New York manufacturing plants, moves that the company previously attributed to attempts to cut costs ahead of the coming 2.3% medical device tax.